• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said Phase III data of its menopause drug, Bio-E-Gel, showed that, depending on dose, about 25 percent to 52 percent of subjects had 100 percent reduction of hot flashes by the end of the study, and that those reductions were statistically significant compared to placebo. Results were presented at the International Society for the Study of Women’s Sexual Health in Lisbon, Portugal. The company submitted a new drug application for Bio-E-Gel last month.

• BioSystems International, of Evry, France, gained an exclusive, worldwide license to Northeastern University’s monoclonal antibody-based biomarker discovery and development platform. Under the agreement, BSI will use the Boston-based university’s platform for biomarker and drug target discovery, validation, development and commercialization. Financial terms were not disclosed.

• ChemDiv Inc., of San Diego, entered a collaboration with Berlex Inc., a U.S. affiliate of Berlin-based Schering AG, to discover lead compounds against several GPCR targets. Under the terms, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities, and collaborate with Berlex’s scientists in the search for new disease therapies. Financial terms were not disclosed.

• Gen-Probe Inc., of San Diego, licensed nonexclusive rights to its hybridization protection assay (HPA) technology to Cambridge, Mass.-based Alnylam Pharmaceuticals Inc. for the development of therapeutic RNA-interfering molecules. Financial terms were not disclosed.

• Mymetics Corp., of Nyon, Switzerland, said the National Institutes of Health agreed to initiate testing of the company’s HIV-AIDS mucosal prophylactic vaccine candidate. The preclinical study will test the vaccine in non-human primates, and will take place in parallel to Mymetics’ ongoing preclinical trial in another primate model.

• Noven Pharmaceuticals Inc., of Miami, said the FDA assigned an April 9 PDUFA date to complete its review of the company’s new drug application for Daytrana (methylphenidate transdermal system) in attention deficit hyperactivity disorder. The drug, which received an approvable letter in December, is licensed globally to Shire plc, of Basingstoke, UK. Upon approval, Noven would be entitled to a $50 million milestone payment.

• Oxford BioMedica plc, of Oxford, UK, said VIRxSYS Corp., of Gaithersburg, Md., licensed its VSV-G viral envelope technology for gene delivery. Under this agreement, VIRxSYS gains rights to use that technology in the production process of an HIV/AIDS product, VRX496, which is in Phase II studies. Oxford BioMedica will receive an up-front license fee, annual maintenance payments, and be entitled to clinical and regulatory milestones and royalties. Further financial terms were not disclosed.

• Targeted Genetics Corp., of Seattle, expects to raise gross proceeds of $5 million through the sale of 12.8 million shares at 39 cents per share to select institutional investors. The company expects net proceeds to be about $4.8 million. It will use the funds for working capital and other general corporate purposes.

No Comments